QUANTICO, Va. (July 10, 2014) -- The U.S. Army Criminal Investigation Command, commonly referred to as CID, recently launched a new centralized recruiting program, part of which features an online ...

SAN FRANCISCO, CA / ACCESS Newswire / August 4, 2025 / CASI Pharmaceuticals, Inc. (CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ ...

SAN FRANCISCO, CA / ACCESS Newswire / August 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with ...

BEIJING, May 15, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical ...

CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, announced FDA ...

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope Phase 1 study in adults with active and chronic active renal allograft AMR planned to initiate AMR is ...

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 15, 2026 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company developing CID-103, a potentially ...

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a leading cause of ...